 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || YT-19 / BriSTAR Immunotech
Trial completion: CD19-Synthetic T Cell Antigen Receptor(STAR)-T in B-cell Malignancies Patients (clinicaltrials.gov) - Feb 1, 2022
P1, N=18, Completed, Sponsor: Hebei Yanda Ludaopei Hospital
Recruiting --> Completed
- SENL-B19 / Hebei Senlang Biotechnology
[VIRTUAL] A Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed (R/R) B Cell Acute Lymphoblastic Leukemia (B-ALL) (Channel 19 (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_1612;
P1
Here, we report pre-clinical and first-in-human phase I trial results of CD19 STAR-T cell therapy for CD19+ R/R B-ALL...Patients received a conditioning regimen of IV fludarabine (25mg/m2/d) and cyclophosphamide (250mg/m2/d) for 3 days followed by a single STAR T-cell infusion...A high CR could be achieved on day 14 with low toxicity. Longer-term observation of these patients and studies of larger patient cohorts are warranted.
- | YT-19 / BriSTAR Immunotech
Enrollment open: CD19-Synthetic T Cell Antigen Receptor(STAR)-T in B-cell Malignancies Patients (clinicaltrials.gov) - Nov 8, 2019
P1, N=18, Recruiting, Sponsor: Hebei Yanda Ludaopei Hospital
Longer-term observation of these patients and studies of larger patient cohorts are warranted. Not yet recruiting --> Recruiting
- | YT-19 / BriSTAR Immunotech
New P1 trial: CD19-Synthetic T Cell Antigen Receptor(STAR)-T in B-cell Malignancies Patients (clinicaltrials.gov) - May 15, 2019
P1, N=18, Not yet recruiting, Sponsor: Hebei Yanda Ludaopei Hospital